Looking at the problem of cytomegalovirus and Epstein-Barr viral infection in gynecology and possible solutions

Authors

  • Л. С. Осипова NMAPE named after P.L. Shupik Clinical Hospital “Feofaniya” Medical department of the State Administration of Affairs, Ukraine
  • А. А. Суханова NMAPE named after P.L. Shupik, Ukraine
  • Е. И. Соколова NMAPE named after P.L. Shupik, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2017.34.32-39

Keywords:

cytomegalovirus infection, Epstein-Barr viral infection, inosine pranobex, immune system, pregnancy, Groprinosin

Abstract

In recent years, there has been an increase in the number of patients suffering from chronic recurrent herpes-viral infections, which in many cases are accompanied by a pronounced disturbance in overall well-being and a number of therapeutic complaints. In particular, on transplantology and gynecology often have diseases and syndromes caused by cytomegalovirus (type V herpes viruses) and Epstein-Barr virus (type IV herpes viruses). The article presents the results of the effectiveness and experience of using an antiviral drug with the immunomodulatory action of Groprinosin® (inosine pranobex) in the treatment of chronic persistent conditions caused by cytomegalovirus infection and infection of the Epstein-Barr virus.

Patients with verified cytomegalovirus infection and Epstein-Barr virus infection were examined. Group I included 56 women with active cytomegalovirus infection; group II – 49 women with active Epstein-Barr virus infection. The control group consisted of 30 healthy women.

All patients received in complex therapy Groprinosin® 50 mg per kg of body weight per day for 2 weeks, then 2 tablets (1000 mg) once a day, regardless of body weight for 2 weeks (3 such courses during the 3 months). The daily dose of Groprinosin® was divided into 3–4 doses.

After 3 months, the cytomegalovirus DNA was detected in spittle of 3 (5.3%) patients of group I, Epstein-Barr virus DNA – in 2 (4.0%) patients of group II. After treatment in patients receiving complex therapy Grosprinosin®, the quantitative indices of T-lymphocyte subpopulations were restored and their imbalance was eliminated (the immunoregulatory index was normalized), the same dynamics was also observed with regard to the number of natural killers.

Based on the conducted studies, it was found that the inclusion of Grosprinosin® in the complex therapy of cytomegalovirus infection and infection with the Epstein-Barr virus promotes an increase in the immunological reactivity of the organism, allowing to significantly improve the clinical course of the disease. Grosrinosin® is well tolerated by patients and can be recommended for the treatment of both of these infections.

Author Biographies

Л. С. Осипова, NMAPE named after P.L. Shupik Clinical Hospital “Feofaniya” Medical department of the State Administration of Affairs

PhD, associate professor at the Department of Clinical Laboratorial Immunology and Allergology;

Head of Laboratory of Clinical Immunology;

Chief specialist in immunology

А. А. Суханова, NMAPE named after P.L. Shupik

MD, professor at the Department of Obstetrics, Gynecology and Reproductology 

Е. И. Соколова, NMAPE named after P.L. Shupik

Postgraduate student at the Department of Obstetrics, Gynecology and Reproductology

References

  1. Bakun, O.V. “Investigation of systemic immunity in women with infertility.” Reproductive health of women 2.31 (2007): 181–3.
  2. Vasylieva, N.A., Kovalchuk, M.T. “Effect of cytomegalovirus infection on pregnancy.” Infectious diseases 4 (2006): 16–20.
  3. Havryliuk, A.M. “Immunological causes of female infertility.” Medical aspects of women health 5.14 (2008): 4–9.
  4. Dobrokhotova, Y.E., Jobava, E.M., Ozerova, R.I. Non-developing pregnancy. Мoscow (2010): 44–8.
  5. Dolgushina, N.V., Makatsariya, A.D. Viral infections in pregnant women. Moscow. Triada X (2004): 137 p.
  6. Isakov, V.A., Selkov, S.A., Moshetova, L.K., Chernakova, G.M. Modern therapy of herpes-viral infections: A guide for doctors. St. Petersburg. Moscow (2004): 168 p.
  7. Kazmirchuk, V.E., Maltsev, D.V. “Recommendations for the treatment of herpes-viral infections of humans.” Ukrainian medical review 5.91 (2012): 3–11.
  8. Kisteneva, L.B., Cheshyk, S.G. “Cytomegalovirus infection in women with weighed obstetric anamnesis.” Epidemiology and infectious diseases 3 (2014): 25–9.
  9. Kramarev, S.O., Palatna, L.A., Golovach, O.V., et al. New aspects in the treatment of infectious mononucleosis in children. In: Collection of scientific, practical and clinical-experimental works “Efficiency of Groprinosin in treatment of viral infectious diseases and immune-deficiencies.” Kyiv. KMAPE (2002).
  10. Kudashov, N.I. “Cytomegalovirus infection in newborns: diagnosis and treatment.” The attending physician 3 (2006): 73–8.
  11. Lyuboshenko, Т.М. “Comparative evaluation of clinical and immunological parameters of patients with cytomegalovirus and Epstein-Barr virus infections.” Fundamental researches 7.5 (2014): 988–92.
  12. Malashenkova, I.K., Didkovskiy, N.A., Sarsania, Z.S., et al. “Clinical forms of chronic Epstein-Barr virus infection: diagnosis and treatment.” The attending physician 9 (2003): 32–8.
  13. Mymbayev, O.A., Manukhin, I.B., Tsarev, V.N., et al. “Inosine, a derivative of purines – a natural highly effective immunomodulating agent in difficult patients with impairments in the immune system.” News of Medicine and Pharmacy 19.342 (2010): 8–12.
  14. Nikolsky, I.S., Yurchenko, V.D., Nikolska, K.I. “Associated with chronic active Epstein-Barr infection clinical and immunological syndrome.” Modern infection 3 (2003): 60–2.
  15. Popova, M.V. “The level of circulatory immune complexes and their molecular composition in women with infertility.” Ukrainian medical almanac 10 (2007): 132–3.
  16. Zhiliev, N.I., Vasilyeva, N.A., Savula, M.M., et al. Perinatal infections: the monograph. Ternopil (2011): 320 p.
  17. Hlibovska, A.I., Boichuk, A.V., Koptiuk, V.I., Shadrina, V.S. “Perinatal aspects of CMV infection.” Infectious diseases 2 (2007): 21–3.
  18. Savchenko, T.N., Aleshkin, V.A., Agaeva, M.I., Shmarina, G.V. “Pregnancy and infection caused by the Epstein-Barr virus.” Women’s Health 1.97 (2015): 17–22.
  19. Chernova, N.I. “The state of systemic immunity in women of reproductive age with cytomegalovirus infection of the urogenital tract.” The Russian bulletin of the obstetrician-gynecologist 2 (2014): 23–8.
  20. Demmler, G.J. Cytomegalovirus. Viral Diseases in Pregnancy, edited by Bernard Gonic. New York (2004): 35–68.
  21. Cannon, M.J., et al. “Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection.” Rev Med Virol 20.4 (2010): 202–13.
  22. Cohen, J.I. “Epstein-Barr virus infection.” N Engl J Med 343 (2000): 481.
  23. Corey, L., Chiang, W.T., Stamm, W.E., Brewer, L. “Effect of isoprinosine on cellular immune responce in initial genital herpes virus infection.” Abstract Clinical Research 27 (1989): 41A.
  24. Golebiowska-Wawrzyniak, M., Markiewicz, K., Kozar, A., et al. “Immunological and clinical study on therapeutic efficiacy of inosine pranobex.” Pol Merkuriusc Lek 19 (2005): 379–82.
  25. Groprinozin – modern capabilities (scientific review). Diseases and antibiotics 2 (2009): 54–7.
  26. Kawa, K. “Epstein-Barr virus-associated di¬seases in humans.” Inf J Hematol 71 (2000): 108–17.
  27. Kim, C.S. “Congenital and perinatal cytomegalovirus infection.” Korean J Pediatr 53.1 (2010): 14–20.
  28. Uppuluri, R., Shah, I. Cytomegalovirus infection and liver disease in neonates. Pediatric liver CME-2010: Conference abstract.

Downloads

Published

2017-04-30

How to Cite

Осипова, Л. С., Суханова, А. А., & Соколова, Е. И. (2017). Looking at the problem of cytomegalovirus and Epstein-Barr viral infection in gynecology and possible solutions. REPRODUCTIVE ENDOCRINOLOGY, (34), 32–39. https://doi.org/10.18370/2309-4117.2017.34.32-39

Issue

No. 34 (2017)

Section

Gynecology

License

Copyright (c) 2017 Л. С. Осипова, А. А. Суханова, Е. И. Соколова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.